Home
World's First Fully Automated AI Scientist Robin Disrupts Traditional Research in Just Two Hours

FutureHouse, a non-profit research organization, published a landmark study in Nature, revealing Robin—the world’s first multi-agent AI system capable of full closed-loop automation in scientific discovery. In under two hours, Robin accomplished work that typically requires human scientists nearly four months, or roughly 900 hours.
A tireless research team
Robin’s innovation stems from its integration of three specialized AI agents, linking hypothesis generation to validation. The "Crow" agent rapidly scans extensive literature to formulate experimental strategies, the "Falcon" agent performs in-depth evaluations, and the "Finch" agent handles data analysis, independently writing code and generating rigorous statistical charts.
In a practical test focused on dry age-related macular degeneration (dAMD), Robin processed hundreds of documents in just thirty minutes. It accurately identified the core pathogenic mechanism—impaired phagocytic function of retinal pigment epithelial cells—and precisely screened multiple potential drugs from a large library, significantly accelerating the early stages of drug development.
Autonomous pharmacological insights and new pathways
Following in vitro cell experiments by human scientists based on Robin’s candidate list, "Ripasudil," a glaucoma drug, was confirmed to have strong repurposing potential. Remarkably, when analyzing experimental data, Robin autonomously designed an RNA sequencing (RNA-seq) plan, successfully uncovering the drug’s underlying pharmacological mechanisms.
During data analysis, Robin also identified a previously overlooked clue: significant upregulation of the "ABCA1" gene, revealing a new avenue for targeted therapies for this eye disease. This unprecedented efficiency and insight signal the start of a new era in AI-driven scientific discovery.
Related article
Samsung Unveils New Galaxy Device with Deep Gemini AI Integration
Samsung unveiled its latest Galaxy lineup at the recent Unpacked event, featuring foldable smartphones, smartwatches, and next-generation smart glasses. This launch marked a significant software overhaul, driven by a deep integration with Google’s Ge
OpenAI Chief Scientist Warns AI May Soon Enter Self-Improvement Phase, Hopes Industry Will Voluntarily Slow Down
Jakub Pachocki, OpenAI’s Chief Scientist, cautioned that artificial intelligence is advancing at an unprecedented speed, complicating human oversight and control. He urged AI developers to voluntarily decelerate progress to prioritize safety."Self-Im
OpenAI Confirms IPO Delay, Altman Says 2026 Launch Unwise
Generative AI leader OpenAI CEO Sam Altman recently clarified in a Fortune interview that the company is not rushing to launch an initial public offering (IPO). Given current market conditions and technological maturity, targeting a 2026 IPO may not
Related Special Topic Recommendations
Comments (0)
0/500

FutureHouse, a non-profit research organization, published a landmark study in Nature, revealing Robin—the world’s first multi-agent AI system capable of full closed-loop automation in scientific discovery. In under two hours, Robin accomplished work that typically requires human scientists nearly four months, or roughly 900 hours.
A tireless research team
Robin’s innovation stems from its integration of three specialized AI agents, linking hypothesis generation to validation. The "Crow" agent rapidly scans extensive literature to formulate experimental strategies, the "Falcon" agent performs in-depth evaluations, and the "Finch" agent handles data analysis, independently writing code and generating rigorous statistical charts.
In a practical test focused on dry age-related macular degeneration (dAMD), Robin processed hundreds of documents in just thirty minutes. It accurately identified the core pathogenic mechanism—impaired phagocytic function of retinal pigment epithelial cells—and precisely screened multiple potential drugs from a large library, significantly accelerating the early stages of drug development.
Autonomous pharmacological insights and new pathways
Following in vitro cell experiments by human scientists based on Robin’s candidate list, "Ripasudil," a glaucoma drug, was confirmed to have strong repurposing potential. Remarkably, when analyzing experimental data, Robin autonomously designed an RNA sequencing (RNA-seq) plan, successfully uncovering the drug’s underlying pharmacological mechanisms.
During data analysis, Robin also identified a previously overlooked clue: significant upregulation of the "ABCA1" gene, revealing a new avenue for targeted therapies for this eye disease. This unprecedented efficiency and insight signal the start of a new era in AI-driven scientific discovery.
Samsung Unveils New Galaxy Device with Deep Gemini AI Integration
Samsung unveiled its latest Galaxy lineup at the recent Unpacked event, featuring foldable smartphones, smartwatches, and next-generation smart glasses. This launch marked a significant software overhaul, driven by a deep integration with Google’s Ge
OpenAI Chief Scientist Warns AI May Soon Enter Self-Improvement Phase, Hopes Industry Will Voluntarily Slow Down
Jakub Pachocki, OpenAI’s Chief Scientist, cautioned that artificial intelligence is advancing at an unprecedented speed, complicating human oversight and control. He urged AI developers to voluntarily decelerate progress to prioritize safety."Self-Im
OpenAI Confirms IPO Delay, Altman Says 2026 Launch Unwise
Generative AI leader OpenAI CEO Sam Altman recently clarified in a Fortune interview that the company is not rushing to launch an initial public offering (IPO). Given current market conditions and technological maturity, targeting a 2026 IPO may not











